Researchers this month published early Phase III results for an experimental drug they're calling GLP-3. The finding that turned heads: participants saw measurable drops in both fasting blood sugar and body weight. At the same time. From a single compound.
GLP-1 drugs like Ozempic already changed what doctors think about weight loss. But simultaneous blood sugar control from the same compound is a different category of result — and the research community flagged it. The drug remains years from any prescription. Long-term safety data isn't in yet.
What the trial showed
Participants recorded fasting glucose reductions alongside weight loss across the study window. The compound appears to act on metabolic pathways differently from existing GLP-1 injections, though the precise mechanism is still being studied.
"Movement on two markers at once — weight and blood sugar — is exactly the direction this field has been working toward." — lead study investigator
The timing matters. An estimated one in three American adults has prediabetes, most without knowing it. Research published earlier this year found that returning blood sugar to normal range cuts the risk of cardiovascular death by 58%. Against that backdrop, a single drug hitting both problems is significant news.
What people are doing while they wait
The drug won't be at a pharmacy for years. That hasn't slowed the search. Within hours of the announcement, search traffic for blood sugar support, berberine, and metabolic health spiked — a pattern that's repeated with every major GLP headline since 2022.
Berberine has been at the center of that search. A compound found in several plants and studied for decades for its effect on glucose metabolism, it's attracted renewed attention as a lower-cost option for people either priced out of prescription treatments or unwilling to wait for them.
The price barrier
Brand-name GLP-1 injections run over $1,000 a month without insurance. Insurers have been pulling coverage steadily through 2025 and into 2026. For most households, the prescription option is already off the table — which explains why every trial announcement sends people searching for alternatives.
The rest of the picture
The people paying closest attention to this news tend to be carrying more than one health concern. Chronic blood sugar elevation affects nerves, joints, circulation, and hearing over time. The same 50-year-old searching for metabolic answers is often also dealing with stiff knees, nerve discomfort in the feet, or a ringing in one ear that started a few years ago.
None of these are separate conversations. Which is why, for anyone in that age group watching this month's findings, the story doesn't end at blood sugar.
For informational purposes only. Not medical advice. Supplement statements not evaluated by the FDA. Consult a healthcare professional before starting any new regimen.
